Renoprotective and antioxidant effects of cilnidipine in hypertensive patients
Hypertension Research, 07/18/2012  Clinical Article

Soeki T et al. – Cilnidipine, but not amlodipine, ameliorated urinary albumin excretion and decreased urinary 8–OHdG and L–FABP in the hypertensive patients. Cilnidipine probably exerts a greater renoprotective effect through its antioxidative properties.

• A total of 35 hypertensive patients receiving a rennin–angiotensin system inhibitor were randomly assigned to a cilnidipine (n=18; 10mg per day cilnidipine titrated to 20mg per day) or amlodipine (n=17; 5mg per day amlodipine titrated to 10mg per day) group; the target blood pressure (BP) was set at 130/85mmHg.

• After 6 months of treatment, systolic and diastolic BPs were significantly reduced in both of the groups, without any significant difference between the groups.
• The urinary albumin, 8–hydroxy–2'–deoxyguanosine (OHdG) and liver–type fatty–acid–binding protein (L–FABP) to creatinine ratios significantly decreased in the cilnidipine group (P<0.05) compared with those in the amlodipine group.
• The reductions in urinary albumin, 8–OHdG and L–FABP were not correlated with the change in systolic BP.